This author has not written his bio yet.
But we are proud to say that Andrew Humphreys contributed 3897 entries already.
The head of the U.S. Centers for Disease Control and Prevention said on Feb. 14 it is “absolutely” too soon to lift mask mandates, citing daily Covid-19 case numbers that despite recent declines remain more than double the levels seen the summer of 2020.
Israel’s largest healthcare provider reported a 94% drop in symptomatic Covid-19 infections among 600,000 people who received two doses of Pfizer’s vaccine in the country’s biggest study to date.
A Covid-19 vaccine candidate developed by Sanofi and U.S. group Translate Bio “will not be ready this year,” the French drugmaker’s chief executive told Le Journal du Dimanche newspaper.
The University of Oxford launched a study to assess the safety and immune response of the Covid-19 vaccine the company has developed with AstraZeneca Plc in children for the first time.
Australia’s second most populous state Victoria entered a five-day lockdown on Feb. 13 as authorities raced to prevent a third wave of Covid-19 cases sparked by the highly infections UK variant.
The U.S. Food and Drug Administration approved Pfizer Inc.’s supplemental Biologics License Application for Panzyga to treat adult patients with a rare neurological disease of the peripheral nerves called chronic inflammatory demyelinating polyneuropathy (CIDP).
The U.S. Centers for Disease Control and Prevention said the agency had administered 48,410,558 doses of Covid-19 vaccines in the country as of the morning of Feb. 12 and delivered 69,014,725 doses.
Chinese authorities refused to provide World Health Organization investigators with raw, personalized data on early Covid-19 cases that could help them determine how and when the coronavirus first began to spread in China, the Wall Street Journal reported, citing WHO investigators.
Amicus Therapeutics announced topline results from the Phase III PROPEL pivotal trial of AT-GAA (cipaglucosidase alfa and miglustat) for late-onset Pompe disease.
In a long-running court battle over PCSK9 antibodies, Amgen lost the company’s bid to uphold patent claims for the cholesterol drug Repatha against rival drug Praluent, developed by Sanofi and Regeneron.